Giovanna Finzi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Giovanna Finzi has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Stefano La Rosa
Unit of Pathology, Department of Medicine and Technological Innovation, University of Insubria, Varese, Italy
4 shared publications - Abbas Agaimy
Institute of Pathology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany
1 shared publication - Alessandro De Carli
Retrovirus Center, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
1 shared publication - Alessandro Marando
Department of Hematology, Oncology, and Molecular Medicine, ASST Grande Ospedale Metropolitano Niguarda, Milan 20162, Italy
1 shared publication - Amedeo Sciarra
Valais Hospital
1 shared publication - Angela Dardano
Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
1 shared publication
Latest Publications
- Open Access
- 27 October 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1) , 1364
Non-electrophilic TRPA1 modulator MNP-021 protects neuronal and glial function from diabetes-associated glucotoxicity and neuroinflammation
- 27 October 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1) , 1364
Open AccessNon-electrophilic TRPA1 modulator MNP-021 protects neuronal and glial function from diabetes-associated glucotoxicity and neuroinflammation
- Open Access
- 24 September 2026
- Published by Springer Nature in Virchows Archiv
- p. 1-7
The indolent nature of gastroblastoma. Report of an illustrative case with 28 years of follow-up showing previously unreported immunohistochemical and molecular features
We report the clinical, morphological, ultrastructural, and molecular features of a gastroblastoma diagnosed in a 27-year-old male describing some unreported findings that can help to better understand this very rare tumor. The clinical course lasting 28 years confirms the indolent nature of gastroblastoma, although the disease was metastatic to local lymph nodes and peritoneum at the time of diagnosis. The tumor displayed a predominant monophasic appearance, being composed of epithelial cells with only very rare spindle mesenchymal cells, confirmed at ultrastructural examination. Thorough immunohistochemical investigation demonstrated coexpression of cytokeratins (AE1/AE3, CAM5.2, CK8/18), podoplanin (D2-40), CD56, and NSE in absence of synaptophysin, chromogranin A, DOG1, CD117, CD34, SMA, desmin, vimentin, and S100. In addition, the expression of somatostatin receptor 2 A associated with positive octreoscan and 68Ga-DOTATOC PET imaging may suggest the use of this nuclear medicine approach for the staging of the tumor and to select patients for possible therapy with somatostatin analogues. The tumor was mismatch repair proteins proficient and did not show any mutation in all 60 genes investigated. Interestingly, targeted RNA sequencing identified a previously unreported TAC3::GLI1 fusion that expands the spectrum of genetic aberrations of gastroblastoma.
- 24 September 2026
- Published by Springer Nature in Virchows Archiv
- p. 1-7
Open AccessThe indolent nature of gastroblastoma. Report of an illustrative case with 28 years of follow-up showing previously unreported immunohistochemical and molecular features
We report the clinical, morphological, ultrastructural, and molecular features of a gastroblastoma diagnosed in a 27-year-old male describing some unreported findings that can help to better understand this very rare tumor. The clinical course lasting 28 years confirms the indolent nature of gastroblastoma, although the disease was metastatic to local lymph nodes and peritoneum at the time of diagnosis. The tumor displayed a predominant monophasic appearance, being composed of epithelial cells with only very rare spindle mesenchymal cells, confirmed at ultrastructural examination. Thorough immunohistochemical investigation demonstrated coexpression of cytokeratins (AE1/AE3, CAM5.2, CK8/18), podoplanin (D2-40), CD56, and NSE in absence of synaptophysin, chromogranin A, DOG1, CD117, CD34, SMA, desmin, vimentin, and S100. In addition, the expression of somatostatin receptor 2 A associated with positive octreoscan and 68Ga-DOTATOC PET imaging may suggest the use of this nuclear medicine approach for the staging of the tumor and to select patients for possible therapy with somatostatin analogues. The tumor was mismatch repair proteins proficient and did not show any mutation in all 60 genes investigated. Interestingly, targeted RNA sequencing identified a previously unreported TAC3::GLI1 fusion that expands the spectrum of genetic aberrations of gastroblastoma.
- 30 May 2023
- Published by Springer Nature in Endocrine Pathology
- Vol. 34 (3) , 349-357
Gastric Amphicrine Carcinoma Showing Neuroendocrine and Pancreatic Acinar Cell Differentiation. Lesson from a Challenging Case Opening New Perspectives in the Diagnostic Work-Up of Gastric Neuroendocrine Neoplasms
Amphicrine carcinomas are epithelial neoplasms composed of cells with co-existing exocrine-neuroendocrine phenotype and are challenging lesions from both diagnostic and therapeutic perspectives.Here, we report the case of a 63-year-old male patient with a gastric nodule that was endoscopically biopsied, revealing histological features of a type 3 well-differentiated gastric neuroendocrine tumor (NET). At imaging, the lesion was single and limited to the stomach, but did not present In-111Octreotide uptake, despite SSTR2A immunohistochemical expression. The patient underwent a wedge resection of the gastric wall, with a final pathological diagnosis of amphicrine carcinoma with pancreatic acinar cell and neuroendocrine features (pT1b). Predictive immunohistochemistry showed microsatellite stability and negative HER2 status. Hotspot targeted deep sequencing of 57 genes showed no somatic mutation, in agreement with the low mutational burden reported for gastric amphicrine carcinomas. Due to a low stage of the tumor and the poor performance status of the patient, no additional oncological treatment was administered. The patient was disease-free after 18 months.This unusual case highlights the importance of considering amphicrine carcinoma in the diagnostic work-up of gastric type 3 NET. This can be done by including in the immunohistochemical panel non-neuroendocrine markers, such as the pancreatic acinar cell and glandular ones. Correct pathological diagnosis is pivotal to determine the appropriate staging (NET vs exocrine one) for surgical and oncological management.
- 30 May 2023
- Published by Springer Nature in Endocrine Pathology
- Vol. 34 (3) , 349-357
Gastric Amphicrine Carcinoma Showing Neuroendocrine and Pancreatic Acinar Cell Differentiation. Lesson from a Challenging Case Opening New Perspectives in the Diagnostic Work-Up of Gastric Neuroendocrine Neoplasms
Amphicrine carcinomas are epithelial neoplasms composed of cells with co-existing exocrine-neuroendocrine phenotype and are challenging lesions from both diagnostic and therapeutic perspectives.Here, we report the case of a 63-year-old male patient with a gastric nodule that was endoscopically biopsied, revealing histological features of a type 3 well-differentiated gastric neuroendocrine tumor (NET). At imaging, the lesion was single and limited to the stomach, but did not present In-111Octreotide uptake, despite SSTR2A immunohistochemical expression. The patient underwent a wedge resection of the gastric wall, with a final pathological diagnosis of amphicrine carcinoma with pancreatic acinar cell and neuroendocrine features (pT1b). Predictive immunohistochemistry showed microsatellite stability and negative HER2 status. Hotspot targeted deep sequencing of 57 genes showed no somatic mutation, in agreement with the low mutational burden reported for gastric amphicrine carcinomas. Due to a low stage of the tumor and the poor performance status of the patient, no additional oncological treatment was administered. The patient was disease-free after 18 months.This unusual case highlights the importance of considering amphicrine carcinoma in the diagnostic work-up of gastric type 3 NET. This can be done by including in the immunohistochemical panel non-neuroendocrine markers, such as the pancreatic acinar cell and glandular ones. Correct pathological diagnosis is pivotal to determine the appropriate staging (NET vs exocrine one) for surgical and oncological management.
- Open Access
- 31 March 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (13) , eabo3789
Highly connected 3D chromatin networks established by an oncogenic fusion protein shape tumor cell identity
Cell fate transitions observed in embryonic development involve changes in three-dimensional genomic organization that provide proper lineage specification. Whether similar events occur within tumor cells and contribute to cancer evolution remains largely unexplored. We modeled this process in the pediatric cancer Ewing sarcoma and investigated high-resolution looping and large-scale nuclear conformation changes associated with the oncogenic fusion protein EWS-FLI1. We show that chromatin interactions in tumor cells are dominated by highly connected looping hubs centered on EWS-FLI1 binding sites, which directly control the activity of linked enhancers and promoters to establish oncogenic expression programs. Conversely, EWS-FLI1 depletion led to the disassembly of these looping networks and a widespread nuclear reorganization through the establishment of new looping patterns and large-scale compartment configuration matching those observed in mesenchymal stem cells, a candidate Ewing sarcoma progenitor. Our data demonstrate that major architectural features of nuclear organization in cancer cells can depend on single oncogenes and are readily reversed to reestablish latent differentiation programs.
- 31 March 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (13) , eabo3789
Open AccessHighly connected 3D chromatin networks established by an oncogenic fusion protein shape tumor cell identity
Cell fate transitions observed in embryonic development involve changes in three-dimensional genomic organization that provide proper lineage specification. Whether similar events occur within tumor cells and contribute to cancer evolution remains largely unexplored. We modeled this process in the pediatric cancer Ewing sarcoma and investigated high-resolution looping and large-scale nuclear conformation changes associated with the oncogenic fusion protein EWS-FLI1. We show that chromatin interactions in tumor cells are dominated by highly connected looping hubs centered on EWS-FLI1 binding sites, which directly control the activity of linked enhancers and promoters to establish oncogenic expression programs. Conversely, EWS-FLI1 depletion led to the disassembly of these looping networks and a widespread nuclear reorganization through the establishment of new looping patterns and large-scale compartment configuration matching those observed in mesenchymal stem cells, a candidate Ewing sarcoma progenitor. Our data demonstrate that major architectural features of nuclear organization in cancer cells can depend on single oncogenes and are readily reversed to reestablish latent differentiation programs.
- Open Access
- 1 September 2018
- Published by Elsevier in Neurochemistry International
- Vol. 118, 61-72
Mitochondrial alterations in Parkinson's disease human samples and cellular models
- 1 September 2018
- Published by Elsevier in Neurochemistry International
- Vol. 118, 61-72
Open AccessMitochondrial alterations in Parkinson's disease human samples and cellular models
- 10 March 2011
- Published by Springer Nature in Endocrine Pathology
- Vol. 22 (2) , 118-124
Cushing’s Syndrome due to a Pancreatic Neuroendocrine Tumor Metastatic to the Ovaries: a Clinicopathological Description of a Case
We report the case of a 36-year-old woman with Cushing’s syndrome caused by a malignant unresectable neuroendocrine carcinoma of the pancreas that developed bilateral ovarian metastases 7 years after diagnosis. In November 2001, because of abdominal pain and jaundice, the patient underwent radiological investigations and exploratory laparotomy that demonstrated the presence of a 3-cm mass of the head of the pancreas, infiltrating the superior mesenteric vein, associated with enlargement of multiple abdominal lymph nodes and with a liver nodule. Histological examination of one lymph node and of the liver nodule demonstrated the presence of metastases from a well-differentiated neuroendocrine carcinoma showing corticotropin immunoreactivity. A few months later, the patient started to show the clinical symptoms of Cushing’s syndrome and underwent steroid-blocking ketoconazole therapy. The clinical endocrine picture was controlled until the end of 2008, when the endocrine symptoms of the Cushing’s syndrome worsened and bilateral ovarian tumors appeared. Hysteroannexectomy was performed and ovarian tumors were found to be metastases from a well-differentiated neuroendocrine carcinoma with morphological and immunohistochemical features overlapping those observed in 2002. The clinical situation worsened and the patient died in November 2009. The clinical aspects and the problems in the differential diagnosis are discussed.
- 10 March 2011
- Published by Springer Nature in Endocrine Pathology
- Vol. 22 (2) , 118-124
Cushing’s Syndrome due to a Pancreatic Neuroendocrine Tumor Metastatic to the Ovaries: a Clinicopathological Description of a Case
We report the case of a 36-year-old woman with Cushing’s syndrome caused by a malignant unresectable neuroendocrine carcinoma of the pancreas that developed bilateral ovarian metastases 7 years after diagnosis. In November 2001, because of abdominal pain and jaundice, the patient underwent radiological investigations and exploratory laparotomy that demonstrated the presence of a 3-cm mass of the head of the pancreas, infiltrating the superior mesenteric vein, associated with enlargement of multiple abdominal lymph nodes and with a liver nodule. Histological examination of one lymph node and of the liver nodule demonstrated the presence of metastases from a well-differentiated neuroendocrine carcinoma showing corticotropin immunoreactivity. A few months later, the patient started to show the clinical symptoms of Cushing’s syndrome and underwent steroid-blocking ketoconazole therapy. The clinical endocrine picture was controlled until the end of 2008, when the endocrine symptoms of the Cushing’s syndrome worsened and bilateral ovarian tumors appeared. Hysteroannexectomy was performed and ovarian tumors were found to be metastases from a well-differentiated neuroendocrine carcinoma with morphological and immunohistochemical features overlapping those observed in 2002. The clinical situation worsened and the patient died in November 2009. The clinical aspects and the problems in the differential diagnosis are discussed.